Download PDF
Exp Clin Endocrinol Diabetes 2024; 132(02): 57-62
DOI: 10.1055/a-2166-6859
German Diabetes Associaton: Clinical Practice Guidelines

Position Paper on Lipid Therapy in Patients with Diabetes Mellitus

A Joint Statement by the Commission on Lipometabolism and The Heart and Diabetes Working Group of the German Diabetes Society (DDG), The Diabetes, Obesity, and Metabolism Section of The German Society of Endocrinology (DGE), The Heart and Diabetes Working Group of the German Cardiology Society (DGK) and The Joint Heart – Hormones – Diabetes Working Group of the DGK, DGE and DDG
Klaus G. Parhofer
1   Department of Internal Medicine IV – Grosshadern, LMU Klinikum, Munich, Germany
,
Andreas L. Birkenfeld
2   Department of Internal Medicine IV, University Hospital, Tübingen
3   Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, German Center for Diabetes Research (DZD e. V.) Germany
,
Wilhelm Krone
4   Center for Endocrinology, Diabetology and Preventive Medicine, University Hospital Cologne, Cologne, Germany
,
Michael Lehrke
5   Department of Internal Medicine I – Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
,
Nikolaus Marx
5   Department of Internal Medicine I – Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
,
Martin Merkel
6   Endocrinologikum Hamburg, Hamburg, Germany
,
Katharina S. Schütt
5   Department of Internal Medicine I – Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
,
Andreas Zirlik
7   Department of Internal Medicine – Division of Cardiology, LKH University Hospital Graz, Medical University Graz, Austria
,
Dirk Müller-Wieland
5   Department of Internal Medicine I – Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital Aachen, Aachen, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Key words

diabetic dyslipidemia, diabetic dyslipoproteinemia, hypertriglyceridaemia


Publication History

Article published online:
15 January 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
    CrossrefPubMedGoogle Scholar
  • 2 Jacobson TA, Ito MK, Maki KC. et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1 – full report. J Clin Lipidol 2015; 9: 129-169
    CrossrefPubMedGoogle Scholar
  • 3 Jacobson TA, Maki KC, Orringer CE. et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol 2015; 9: S1-S122.e1
    CrossrefPubMedGoogle Scholar
  • 4 Jellinger PS, Handelsman Y, Rosenblit PD. et al American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease – Executive Summary. Complete Appendix to Guidelines available at http://journals.aace.com Endocr Pract 2017; 23: 479-497
    CrossrefPubMedGoogle Scholar
  • 5 American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2023. Diabetes Care 2023; 46: S158-S190
    CrossrefPubMedGoogle Scholar
  • 6 Gregg EW, Li Y, Wang J. et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014; 370: 1514-1523
    CrossrefPubMedGoogle Scholar
  • 7 Yusuf S, Hawken S, Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study): case-control study. Lancet 2004; 364: 937-952
    CrossrefPubMedGoogle Scholar
  • 8 Nordestgaard BG, Langsted A, Mora S. et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points – a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37: 1944-1958
    CrossrefPubMedGoogle Scholar
  • 9 Sniderman AD, De Graaf J, Couture P. et al. Regulation of plasma LDL: the apoB paradigm. Clin Sci (Lond) 2010; 118: 333-339
    CrossrefPubMedGoogle Scholar
  • 10 Parhofer KG. The Treatment of Disorders of Lipid Metabolism. Dtsch Arztebl Int 2016; 113: 261-268
    PubMedGoogle Scholar
  • 11 Nissen SE. et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med 2023; 388: 1353-1364
    CrossrefPubMedGoogle Scholar
  • 12 Moriarty PM, Parhofer KG, Babirak SP. et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J 2016; 37: 3588-3595
    CrossrefPubMedGoogle Scholar
  • 13 Parhofer KG, Laufs U. The Diagnosis and Treatment of Hypertriglyceridemia. Dtsch Arztebl Int 2019; 116: 825-832
    CrossrefPubMedGoogle Scholar
  • 14 Das Pradhan A, Glynn RJ, Fruchart CC. et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med 2022; 387: 1923-1934
    CrossrefPubMedGoogle Scholar
  • 15 Bhatt DL, Steg PG, Miller M. et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019; 380: 11-22
    CrossrefPubMedGoogle Scholar
  • 16 Ewald N, Kloer HU. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. Clin Res Cardiol Suppl 2012; 7: 31-35
    CrossrefPubMedGoogle Scholar